English 
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00
Corticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
Description
Corticobasal syndrome (CBS) is rare clinical syndrome characterized by progressive asymmetrical limb apraxia, parkinsonism, dystonia, and particular cognitive impairments and is characterized by both motor and higher-cortical dysfunctions. Although the CBS was initially thought to be specific to a single pathology, it is increasingly recognized that the syndrome is nonspecific to any one pathology. Many pathologies underlie the corticobasal syndrome, including corticobasal degeneration (CBD) and Alzheimer’s disease (AD). The clinical diagnostic accuracy of CBS is the lowest amongst all diseases (about 50%) and known to affect an individual between age 50 and 70.
Corticobasal syndrome (CBS) – Prevalence (Epidemiology)
The total prevalent cases of Corticobasal syndrome (CBS) in the G7 countries is expected to reach 60,000 by 2030 at a CAGR of 0.5%. According to the National Organization for Rare Disorders, CBS tend to affect both males and females equally and usually, estimated to affect 5 people per 100,000, with approximately 62-92 new cases per year per 100,000 people.CBS is known to be associated with multiple clinical associated conditions i.e. Corticobasal degeneration (CBD), Progressive supranuclear palsy (PSP), Alzheimer’s disease (AD), Pick’s disease, Dementia lacking specific histology (DLDH), Parkinson’s disease (PD), Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP43) FTLD-TDP43 + Motor neuron disease (MND), Creutzfeldt- Jacob disease (CJD), Multiple system tauopathy without argyrophilia (MST) and Mixed Disease. Among which, Corticobasal degeneration (CBD) contribute to the highest CBS cases by 45.5%.
Corticobasal syndrome (CBS) – Current Market Size & Forecast Trends
The market size of Corticobasal syndrome (CBS) is expected to increase to $XX million in 2032. Corticobasal syndrome (CBS) current treatment includes medications like levodopa, muscle relaxants such as clonazepam, and botulinum toxin injections, Donepezil or memantine. Non-pharmacological strategies include cognitive behavioral therapy, occupational therapy, and lifestyle modifications, focused to reduce the symptoms of CBS patients.Emerging therapies for the treatment of Corticobasal syndrome (CBS) include the Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals), currently in phase 2 trials for CBS and the gene therapy- TSHA-113 which is under preclinical development by Taysha Gene Therapies. Primary drivers of market growth for Corticobasal syndrome (CBS) will be the launch of the Fasudil (BRAVYL), a small molecule by Woolsey Pharmaceuticals. Corticobasal syndrome (CBS) market will be dependent mostly on the shares from Fasudil (Woolsey Pharmaceuticals) due to the limited number of effective therapies during the forecast period.
Report Highlights
- Corticobasal Syndrome (CBS)-Current Market Trends
- Corticobasal Syndrome (CBS)-Current & Forecasted Cases across the G7 Countries
- Corticobasal Syndrome (CBS)-Market Opportunities and Sales Potential for Agents
- Corticobasal Syndrome (CBS)-Patient-based Market Forecast to 2032
- Corticobasal Syndrome (CBS)-Untapped Business Opportunities
- Corticobasal Syndrome (CBS)-Product Positioning Vis-a-vis Competitors’ Products
- Corticobasal Syndrome (CBS)-KOLs Insight
Additional information
| Price | Single User License, 2-3 User License, Site License, Enterprise License |
|---|
Table of Contents
- Executive Summary
- Key Findings
- Corticobasal Syndrome (CBS) Disease Background
- Corticobasal Syndrome (CBS) Disease Definition
- Symptoms & Causes
- Corticobasal Syndrome (CBS): Clinical Symptoms
- Corticobasal Syndrome Pathology
- Corticobasal Syndrome Genetics
- Corticobasal Syndrome (CBS) Differential Diagnosis
- Epidemiology and Patient Populations
- Key Findings
- Methods and data Sources
- Country Specific Prevalent Populations (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Clinical Manifestations Associated Corticobasal Syndrome (CBS) Cases
- Country Specific Diagnosed and Treated Cases of Corticobasal Syndrome (CBS)
- Number of Diagnosed and Drug-Treated Cases of Corticobasal Syndrome (CBS) in the Major Pharmaceutical Markets, 2017-2030
- Key Sources for Corticobasal Syndrome (CBS) Epidemiology and Model Parameters
- United States
- United States Prevalent Populations of Corticobasal Syndrome (CBS)
- United States Clinical Manifestations Associated Cases of Corticobasal Syndrome (CBS)
- United States Diagnosed and Treated Cases of Corticobasal Syndrome (CBS)
- Germany
- Germany Prevalent Populations of Corticobasal Syndrome (CBS)
- Germany Clinical Manifestations Associated Cases of Corticobasal Syndrome (CBS)
- Germany Diagnosed and Treated Cases of Corticobasal Syndrome (CBS)
- France
- France Prevalent Populations of Corticobasal Syndrome (CBS)
- France Clinical Manifestations Associated Cases of Corticobasal Syndrome (CBS)
- France Diagnosed and Treated Cases of Corticobasal Syndrome (CBS)
- Italy
- Italy Prevalent Populations of Corticobasal Syndrome (CBS)
- Italy Clinical Manifestations Associated Cases of Corticobasal Syndrome (CBS)
- Italy Diagnosed and Treated Cases of Corticobasal Syndrome (CBS)
- Spain
- Spain Prevalent Populations of Corticobasal Syndrome (CBS)
- Spain Clinical Manifestations Associated Cases of Corticobasal Syndrome (CBS)
- Spain Diagnosed and Treated Cases of Corticobasal Syndrome (CBS)
- United Kingdom
- United Kingdom Prevalent Populations of Corticobasal Syndrome (CBS
- United Kingdom Clinical Manifestations Associated Cases of Corticobasal Syndrome (CBS)
- United Kingdom Diagnosed and Treated Cases of Corticobasal Syndrome (CBS)
- Japan
- Japan Prevalent Populations of Corticobasal Syndrome (CBS)
- Japan Clinical Manifestations Associated Cases of Corticobasal Syndrome (CBS)
- Japan Diagnosed and Treated Cases of Corticobasal Syndrome (CBS)
- United States
- Current Therapies and Medical Practice
- Treatments & Medical Practices
- Treatment patterns in CBS
- Unmet Needs
- Emerging Therapies
- Pipeline Overview
- Therapeutic Developments Pipeline for Corticobasal Syndrome (CBS)
- Product Analysis
- Fasudil (Woolsey)
- Product Profile
- Clinical Development
- Sales Market Opportunity by 2032
- TSHA-113 (Taysha Gene Therapies)
- Product Profile
- Others
- Fasudil (Woolsey)
- Product Analysis
- Future Treatment Paradigm
- Corticobasal Syndrome (CBS) Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Annual Cost of Current & Emerging Therapies
- Market Outlook
- Key Findings
- Country Specific Market Forecast to 2032
- Sales of Drugs to Treat Corticobasal Syndrome (CBS) in the Major Pharmaceutical Markets, 2017-2030
- Patient Share of Corticobasal Syndrome (CBS) Therapies and by Drug
- Market Forecast by Country
- United States
- United States Market for Corticobasal Syndrome (CBS) 2022-2032 (USD Million)
- United States Market for Corticobasal Syndrome (CBS) by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Corticobasal Syndrome (CBS) 2022-2032 (USD Million)
- Germany Market for Corticobasal Syndrome (CBS) by Therapies 2022-2032 (USD Million)
- France
- France Market for Corticobasal Syndrome (CBS) 2022-2032 (USD Million)
- France Market for Corticobasal Syndrome (CBS) by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Corticobasal Syndrome (CBS) 2022-2032 (USD Million)
- Italy Market for Corticobasal Syndrome (CBS) by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Corticobasal Syndrome (CBS) 2022-2032 (USD Million)
- Spain Market for Corticobasal Syndrome (CBS) by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Corticobasal Syndrome (CBS) 2022-2032 (USD Million)
- United Kingdom Market for Corticobasal Syndrome (CBS) by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Corticobasal Syndrome (CBS) 2022-2032 (USD Million)
- Japan Market for Corticobasal Syndrome (CBS) by Therapies 2022-2032 (USD Million)
- Market Drivers and Constraints
- What Factors Are Driving the Market for Corticobasal Syndrome (CBS)?
- What Factors Are Constraining the Market for Corticobasal Syndrome (CBS)?
- Appendix
- Report Methodology
Sample Enquiry
Related products
-
High grade intraepithelial lesion (HSIL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00 Select options -
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022
$2,700.00 – $8,100.00Select optionsAnti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
-
Neuromyelitis Optica Spectrum Disorder (NMOSD) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsWe see great future treatment opportunity for the NMOSD market because of the launch of the emerging therapies like Telitacicept (RC-Pharma), Ravulizumab (Alexion Pharmaceuticals), SHR1459 (Reistone Biopharma) and others potential therapies, providing the global solution for “optic neuritis with spinal cord manifestations and other neurologic disorders associated with the serum aquaporin-4 immunoglobulin G antibodies”. -
Head and neck squamous cell carcinoma (HNSCC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2033
$7,500.00 – $22,500.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the Head and neck squamous cell carcinoma (HNSCC) therapeutics market for HNSCC s was worth US$ Billion in 2023 and is predicted to grow at a 13.9% CAGR to reach US$ 7.5 Billion by 2033.